Marco HEOR provides pharmacoeconomics and health technology assessment (HTA) teams with a structured, transparent framework to compare real-world evidence on Melanoma against clinical and HTA models. The system integrates international HTA guidelines, registry data and clinical trial results to support access and reimbursement decisions.
Some answers to questions we often receive
Marco HEOR centralizes clinical and economic evidence for Melanoma, identifies appropriate comparators per each country's HTA framework, synthesizes clinical trial and real-world study data, and generates structured summaries facilitating dossier construction for agencies such as NICE, IQWiG or ICER.
Marco HEOR provides the epidemiological evidence base (incidence, prevalence, treatment rates) and comparative efficacy data to build budget impact models for Melanoma. The system identifies key uncertainty parameters and facilitates sensitivity analyses required by HTA bodies.
Marco HEOR facilitates quantification of the differential clinical value of a new Melanoma therapy versus standard of care, identifying value attributes most relevant to local payers. This structured base supports evidence-based price negotiation arguments with payers and health ministries.
Yes. Marco HEOR integrates and synthesizes real-world evidence studies for Melanoma: patient registries, observational studies, administrative database analyses and post-marketing studies, enabling cross-referencing of RWE results with clinical trial data to identify transferability and evidence gaps.
Marco HEOR integrates leading international HTA frameworks (NICE, IQWiG and international frameworks for immunotherapy and BRAF-targeted therapy) and their methodologies specific to Melanoma, including relevant endpoint criteria, cost-effectiveness thresholds, analysis perspectives and indirect comparative evidence requirements for new therapies.
Yes. Marco HEOR facilitates design and monitoring of managed entry agreements for Melanoma, identifying outcomes to track, response thresholds and evaluation periods per HTA framework recommendations and experience from countries with the most advanced managed entry track records.
The treatment sequencing question in BRAF-mutated melanoma has enormous economic implications that current HEOR models do not capture well.